Portage Biotech Inc
NASDAQ:ATON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Portage Biotech Inc
Selling, General & Administrative
Portage Biotech Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Portage Biotech Inc
NASDAQ:ATON
|
Selling, General & Administrative
-$8.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-94%
|
CAGR 10-Years
-20%
|
|
Portage Biotech Inc
Glance View
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
See Also
What is Portage Biotech Inc's Selling, General & Administrative?
Selling, General & Administrative
-8.2m
USD
Based on the financial report for Sep 30, 2025, Portage Biotech Inc's Selling, General & Administrative amounts to -8.2m USD.
What is Portage Biotech Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-20%
Over the last year, the Selling, General & Administrative growth was -63%. The average annual Selling, General & Administrative growth rates for Portage Biotech Inc have been 3% over the past three years , -94% over the past five years , and -20% over the past ten years .
